Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718931 | 0.89 | PGR (0.47) | PGRS100A4HTR2BHTR2AHTR2C | |
| SCHEMBL20233477 | 0.88 | PGR (0.46) | PGRS100A4HTR2BHTR2AHTR2C | |
| SCHEMBL13995259 | 0.85 | PGR (0.41) | PGRS100A4HTR2BHTR2AHTR2C | |
| SCHEMBL23252306 | 0.83 | CA2 (0.45) | PGRS100A4HTR2BHTR2AHTR2C | |
| SCHEMBL17882478 | 0.80 | PGR (0.43) | PGRS100A4HTR2BHTR2AHTR2C | |
| SCHEMBL21391593 | 0.78 | PGR (0.42) | PGR | |
| SCHEMBL20233481 | 0.78 | PGR (0.42) | PGR | |
| SCHEMBL17716753 | 0.78 | PGR (0.42) | PGRHTR2BHTR2AHTR2CTDP2 | |
| SCHEMBL1240051 | 0.77 | S100A4 (0.42) | PGRS100A4HTR2BHTR2AHTR2C | |
| SCHEMBL26119454 | 0.76 | MAPK1 (0.53) | PGRS100A4HTR2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063640-A1 | Reagents for Directed Biomarker Signal Amplification | SIRIGEN II LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| US-12345713-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-12253525-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-03-18 | — | — | US | disclosed |
| US-12241898-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-12235274-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-12153050-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-11-26 | — | — | US | disclosed |
| US-12111321-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| US-20240272166-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN II LIMITED (GB) | 2024-08-15 | — | — | US | disclosed |
| CN-116003346-B | Fluorescent material for detecting dimethyl sulfide with high selectivity as well as preparation method and application thereof | 山东省分析测试中心 | 2024-05-31 | — | — | CN | disclosed |
| EP-3981819-B1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN II LTD (GB) | 2024-02-28 | — | — | EP | disclosed |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7993747-B2 | Light emitting devices and compositions comprising lumophore-functionalized nanoparticles | NITTO DENKO CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7993747-B2 | Light emitting devices and compositions comprising lumophore-functionalized nanoparticles | NITTO DENKO CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| WO-2011091086-A1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011091086-A1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| CN-101525297-A | 9,9-dialkyl-2,7-dihydroxy-3,6-diamino TI-4,fluorene hydrochloride and preparation method thereof | HUAIHAI INST TECHNOLOGY | 2009-09-09 | — | — | CN | disclosed |
| WO-2007136588-A1 | LIGHT EMITTING DEVICES AND COMPOSITIONS | NITTO DENKO CORPORATION (JP) | 2007-11-29 | — | — | WO | disclosed |
| US-20070262302-A1 | LIGHT EMITTING DEVICES AND COMPOSITIONS | NITTO DENKO CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070262302-A1 | LIGHT EMITTING DEVICES AND COMPOSITIONS | NITTO DENKO CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12253525-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | PGR 2229/4885S100A4 46/4885HTR2B 4273/4885 |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | PGR 2865/4885S100A4 46/4885HTR2B 4216/4885 |
| US-12235274-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | PGR 2229/4885S100A4 46/4885HTR2B 4273/4885 |
| US-12345713-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | PGR 2229/4885S100A4 46/4885HTR2B 4273/4885 |
| US-12111321-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | PGR 2229/4885S100A4 46/4885HTR2B 4273/4885 |
| US-12241898-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | PGR 2229/4885S100A4 46/4885HTR2B 4273/4885 |
| US-20260063640-A1 | Reagents for Directed Biomarker Signal Amplification | RNGTT, RNMT, DNMT3L | PGR 1618/4885S100A4 538/4885HTR2B 1334/4885 |
| US-20240272166-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | PGR 2865/4885S100A4 46/4885HTR2B 4216/4885 |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | PGR 2865/4885S100A4 46/4885HTR2B 4216/4885 |
| US-12153050-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | PGR 2229/4885S100A4 46/4885HTR2B 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.